LeMaitre Vascular, Inc. (NASDAQ:LMAT) Director Bridget A. Ross Sells 2,500 Shares

Key Points

• Bridget A. Ross, Director of LeMaitre Vascular, sold 2,500 shares at an average price of $94.00, totalizing $235,000, representing a 46.16% decrease in her ownership.
• The company reported $0.60 earnings per share for the last quarter, exceeding estimates of $0.57, with a revenue of $63.15 million, a 15.0% increase year-over-year.
• LeMaitre Vascular declared a quarterly dividend of $0.20 per share, with an annualized yield of 0.8% for shareholders of record by August 21st.

LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report) Director Bridget A. Ross sold 2,500 shares of the stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $94.00, for a total transaction of $235,000.00. Following the transaction, the director directly owned 2,916 shares of the company's stock, valued at approximately $274,104. This trade represents a 46.16% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

LeMaitre Vascular Stock Down 0.9%

LMAT traded down $0.87 on Monday, hitting $95.04. 120,983 shares of the company were exchanged, compared to its average volume of 189,653. The firm has a 50-day moving average price of $84.56 and a two-hundred day moving average price of $86.34. The company has a current ratio of 13.96, a quick ratio of 11.74 and a debt-to-equity ratio of 0.46. LeMaitre Vascular, Inc. has a twelve month low of $71.42 and a twelve month high of $109.58. The company has a market cap of $2.15 billion, a price-to-earnings ratio of 46.14, a price-to-earnings-growth ratio of 2.47 and a beta of 0.79.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The medical instruments supplier reported $0.60 EPS for the quarter, topping analysts' consensus estimates of $0.57 by $0.03. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%. The business had revenue of $63.15 million during the quarter, compared to the consensus estimate of $62.48 million. During the same period in the previous year, the company posted $0.52 earnings per share. The business's revenue for the quarter was up 15.0% on a year-over-year basis. On average, equities analysts predict that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 4th. Stockholders of record on Thursday, August 21st will be issued a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date is Thursday, August 21st. LeMaitre Vascular's dividend payout ratio (DPR) is presently 38.83%.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on LMAT shares. Cantor Fitzgerald increased their target price on LeMaitre Vascular from $92.00 to $95.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. Barrington Research raised shares of LeMaitre Vascular from a "market perform" rating to an "outperform" rating and set a $95.00 price target on the stock in a research report on Wednesday, August 6th. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Hold" and an average price target of $98.00.

Institutional Investors Weigh In On LeMaitre Vascular

Institutional investors have recently modified their holdings of the company. Advisors Asset Management Inc. raised its stake in LeMaitre Vascular by 3.0% in the second quarter. Advisors Asset Management Inc. now owns 4,111 shares of the medical instruments supplier's stock valued at $341,000 after buying an additional 118 shares in the last quarter. Federated Hermes Inc. boosted its position in shares of LeMaitre Vascular by 0.4% during the 2nd quarter. Federated Hermes Inc. now owns 39,659 shares of the medical instruments supplier's stock worth $3,294,000 after acquiring an additional 155 shares in the last quarter. Summit Investment Advisors Inc. increased its holdings in shares of LeMaitre Vascular by 8.2% in the 4th quarter. Summit Investment Advisors Inc. now owns 2,122 shares of the medical instruments supplier's stock valued at $196,000 after acquiring an additional 160 shares during the last quarter. Johnson Investment Counsel Inc. raised its position in shares of LeMaitre Vascular by 0.7% during the 2nd quarter. Johnson Investment Counsel Inc. now owns 29,639 shares of the medical instruments supplier's stock worth $2,462,000 after acquiring an additional 211 shares in the last quarter. Finally, Franklin Resources Inc. raised its position in shares of LeMaitre Vascular by 1.6% during the 2nd quarter. Franklin Resources Inc. now owns 13,499 shares of the medical instruments supplier's stock worth $1,121,000 after acquiring an additional 212 shares in the last quarter. 84.64% of the stock is owned by hedge funds and other institutional investors.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.